Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain

Current Medical Research and Opinion

Volumn 20, Issue SUPPL. 2, 2004, Pages

  Galer, Bradley S ^a,b   Gammaitoni, Arnold R ^a   Oleka, Napoleon ^a   Jensen, Mark P ^c,d   Argoff, Charles E ^e  

^a ENDO PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesics; Low back pain; Neuropathic Pain Scale; Pain management

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GABAPENTIN; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; TRAMADOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN SCALE; OPEN STUDY; PAIN ASSESSMENT; PAPULE; PRURITUS; RASH; RATING SCALE; TOPICAL ANESTHESIA;

ADMINISTRATION, CUTANEOUS; ANESTHETICS, LOCAL; FEMALE; HUMANS; LIDOCAINE; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 13144258744     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X12933     Document Type: Article

References (32)

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56
2. Guo HR, Tanaka S, Cameron LL, et al. Back pain among workers in the United States: national estimates and workers at high risk. Am J Ind Med 1995;28:591-602
3. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29:79-86
4. Rizzo JA, Abbott TA, III, Berger ML. The labor productivity effects of chronic backache in the United States. Med Care 1998;36:1471-88
5. Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res Manag 2002;7:81-92
6. Moskowitz MH. Pharmacotherapy of neuropathic low back pain. Curr Pain Headache Rep 2003;7:178-87
7. Deyo RA. Drug therapy for back pain: which drugs help which patients? Spine 1996;21:2840-50
8. Garofalo JP, Polatin P. Low back pain: an epidemic in industrialized countries. In: Gatchel RJ, Turk DC, editors. Psychosocial factors in pain. New York (NY): Guilford Press; 1999
9. Sorensen J, Kalman S, Tropp H, Bengtsson M. Can a pharmacological pain analysis be used in the assessment of chronic low back pain? Eur Spine J 1996;5:236-42
10. Masubuchi Y, Saito H, Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J Pharmacol Exp Ther 1998;287:208-13
11. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-7
12. Weinblatt ME. Drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl 1989;83:7-10
13. Ehrlich GE. Low back pain. Bull World Health Organ 2003;81:671-6
14. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves post-herpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
15. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain 2002;18:297-301
16. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
17. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000;59:245-9
18. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40
19. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003;4:321-30
20. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004;12:253-5
21. Argoff CE. New analgesics for neuropathic pain: the lidocaine patch. Clin J Pain 2000;16:S62-S66
22. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 2000;16:205-8
23. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332-8
24. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8
25. Palmer KT, Walsh K, Bendall H, Cooper C, Coggon D. Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. Br Med J 2000;320:1577-8
26. Pruitt SD, Von Korff M. Improving the management of low back pain: a paradigm shift for primary care. In: Turk DC, Gatchel RJ, editors. Psychosocial approaches to pain management: a practitioner's handbook. New York (NY): Guilford Press; 2002
27. Chung K, Lee BH, Yoon YW, Chung JM. Sympathetic sprouting in the dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain model. J Comp Neurol 1996;376:241-52
28. McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993;363:543-6
29. Fields HL, Rowbotham MC. Multiple mechanisms of neuropathic pain: a clinical perspective. In: Gebhart GF, Hammond DL, et al., editors. Proceedings of the 7th World Congress on Pain. Seattle: IASP Press; 1994. p. 437-54
30. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989;38:333-8
31. Laird JM, Carter AJ, Grauert M, Cervero F. Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 2001;134:1742-8
32. Zhang JM, Li H, Munir MA. Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine. Pain 2004;109:143-9